Research and development are at the core of Earth Science Pharma’s operations. From the distinguished members of the Scientific Review Board to the senior executives, everyone in the company is focused on developing the next-generation medical devices, drugs, and vaccines that will fight disease and improve public health.
The first goal of the R&D Team is to finish the testing that will prove that a single sample taken with the MSN-2 device can be used to detect other STI, such as gonorrhea, trichomonase and HPV, from the same sample.
Other R&D projects on the horizon are to expand the capability of the MSN-2 technology, develop more at-home testing devices that will increase access to testing – particularly among women, and developing a prophylactic vaccine to prevent chlamydia.
The Development Team is housed in the company’s manufacturing facility. The new facility is located close to major transit hubs and is flexible in terms of size. The facility will thus grow with the company. At the moment, the facility is undergoing ISO-13485 accreditation, which is the standard for the production of medical devices, and is required for Health Canada and FDA approval for devices that are sold in North America.